Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus DEXONE 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus DEXONE 4.
CORTIFOAM vs DEXONE 4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Category C
Category C
Corticosteroid
Corticosteroid